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Although athymic nude mice are an established model for
the maintenance of human xenografts in vivo (Sharkey et al.,
1978), they can exhibit a high incidence of malignant
lymphomas (Custer et al., 1973) which may be associated
with chronic antigen stimulation resulting in the activation
of endogenous murine leukaemic viruses, MuLV, (Baird et
al., 1982). Also, xenotropic and ectopic MuLV can infect
transplanted tumour cells (Hirsch et al., 1972; Todaro et al.,
1973) and intact virions may be recovered from such
tumours in vitro after passage in mice (Price et al., 1975).
These phenomena can become a serious problem in the
routine handling of human tumours; either because the
resulting tumour could become murine rather than human or
because the addition of murine viral proteins to the comple-
ment of human cell proteins could complicate biochemical
and immunological studies of the tumour as well as efforts
to identify possible human retroviruses endogenous to a
particular tumour.
At the Royal Marsden Hospital there is considerable
interest in the biology and drug sensitivity of malignant
myeloma. The human myeloma cell. line, RPMI-8226,
(Matsuoko et al., 1967) is used routinely in our laboratory
as a model for the disease and it was intended to establish
these cells in vivo as a xenograft. Electron micrographs of the
cells show that they are plasmablastoid with a well
developed endoplasmic reticulum (Figure la). They are
hyperdiploid, exhibit lambda immunoglobulin on the cell
surface as well as HAN PCI, which is characteristic of
plasma cells (Mertens et al., 1985), and have a doubling time
of 40h in vitro (Miller & Bell, 1987).
RPMI-8226 cells are passaged in suspension .in RPMI-
1640 supplemented with 15% foetal calf serum, 20mM
HEPES buffer, 100IUml-I penicillin, and 100pgml-l
streptomycin. Initially an inoculum of 2 x 107 cells was
injected s.c. and bilaterally into the flanks of 2 6-8 week-old
male BALB/c athymic nude mice. After 12 days, tumours
were palpable at each injection site. The growth of these
tumours was monitored during the following 5 days (Figure
2a), after which time the animals were sacrificed by cervical
dislocation and the tumours harvested. There was no
evidence for invasion of tumour cells to the spleen, liver,
lungs or retroperitoneal nodes.
One tumour was frozen in liquid N2 immediately, a
second was dissected, examined with a panel of monoclonal
antibodies and established in vitro. The majority of the
viable cells (>75%) were mouse 'T' lymphocytes. This was
assessed using a fluorescein-conjugated rat anti-mouse
monoclonal antibody directed against murine 'T' cell surface
markers. (MAS 50, Sera-Lab. Crawley Down, Sussex). This
population produced a pure culture within 7 days and had a
doubling time of 11.8h (Figure 2b). The cells all carried the
MAS 50 'T' cell marker and had murine karyotype. Samples
of the cells were examined by electron microscopy (Figure
lb). Unlike the human cell line, the mouse 'T' lymphoma
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(MIT 1) had a poorly developed endoplasmic reticulum and
'C' type virus particles could be seen budding from the
plasmalemma. The murine origin of this lymphoma was
confirmed by chromosome analysis and compared with the
original human cell line. Figure 3a, b shows that the MIT 1
cells had telocentric chromosomes, characteristic of murine
origin, whereas the RPMI-8226 cells do not have this type of
chromosome. In human cells chromosomes are either meta,
sub-meta or acrocentric.
The two remaining tumours, one from each animal were
passaged bilaterally into the flanks of a further group of 16
athymic nude mice (see Figure 4). Large oedematous
tumours, which were palpable on day 11, grew at each
injection site. Animals were sacrificed before the tumours
ulcerated, and samples of tumours were harvested and
dissociated. Examination of these tumour cells with
monoclonal antibodies and by karyotype showed that they
were also murine 'T' lymphomas.
The growth of the tumour which had been stored in liquid
N2 was examined in homozygous and heterozygous immuno-
competent BALB/c mice. The data summarized in Figure 4
show that tumours grew in immunocompetent animals.
However it took 17 days for tumours to reach a mean
diameter of 1 cm in these animals compared with 11 days in
athymic nude mice. In each instance these tumours were
murine 'T' lymphomas. When 5 x 106 MIT 1 cells were used
an inoculum into mice of different phenotype, the time
course of appearance of tumours was similar to that seen in
animals which had received tumour cells from liquid N2 (see
Figure 4). Thus, each of the four tumours, which arose
following the inoculation of the human cell line, RPMI-8226,
into athymic nude mice, resulted from the growth of murine
'T' lymphomas.
In a second experiment, 4 female athymic nude mice were
injected bilaterally in the flank with a bolus of 2 x 107
RPMI-8226 cells. Tumours appeared at two of the injection
sites in separate animals 4 weeks after implantation. One of
these tumours was a murine 'T' lymphoma, the second
consisted of predominantly RPMI-8226 cells. The human
myeloma cells were re-established in vitro. Examination of
their karyotype showed that they are similar to the original
cell line. Virus particles were not detectable using electron
microscopy. No tumour growth occurred in the remaining
two animals even though they received a further inoculation
of 107 RPMI-8226 cells 4 weeks after the original injection.
The observations that all these 'T' lymphomas were of
mouse karyotype, produced tumours in immune-competent
animals and contained 'C' type virus particles suggests that
they resulted from the activation of murine leukaemia virus
MuLV by the human myeloma cell line. Gautsch et al.
(1980) reported the induction of MuLV by an oat cell
carcinoma. However, no data were provided to show that
the karyotype or isoenzyme patterns of the tumour remained
human after passage in vivo. In other systems, the pro-
duction of lymphomas in the lymph nodes and spleen of
athymic nude mice has been ascribed to chronic antigenic
stimulation producing a lymphoproliferative reaction (Baird
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Figure 2 Growth of mouse 'T' lymphoma (a) in athymic nude
mice and; (b) in vitro (MIT 1).
Figure 1 Electron micrographs of (a) RPMI-8226 (human
myeloma), arrow indicates typical well-developed endoplasmic
reticulum characteristic of plasma cells (x 33,000) and; (b) MIT
(mouse 'T' lymphoma) arrow indicates virus particle budding
from the plasmalemma (x 127,000).
et al., 1982). Although there was no evidence for metastatic
spread in the experiments reported herein this may have
been due to the rapid growth of the primary tumours which
necessitated the termination of experiments before the
tumours ulcerated. Our findings concerning the rapid growth
of these tumours are in agreement with those of Sparrow et
al. (1986) who pointed out that since human tumour
xenografts grow relatively slowly, rapid tumour growth and
skin ulceration should alert the investigator of possible
Figure 3 Karyotype of (a) RPMI-8226 (human myeloma)
( x 8,500) and; (b) MIT I (mouse 'T' lymphoma) ( x 9,000).
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Figure 4 Flow diagram to show the attempted growth of RPMI-8226 cells (human myeloma) as xenografts in athymic nude mice.
malignant transformation of endogenous murine cells. The
incidence of 'T' lymphomas in our system (5/6) is much
higher than that reported by other workers. Sparrow et al.
(1986) reported 3 murine fibrosarcomas which arose over a 6
year period from 30 human xenografts. In this respect the
RPMI-8226 cell line appears more effective in initiating the
production of endogenous virus which results in lynmphoma
production than they are of becoming established as a
xenograft. The mechanisms of this virus induction remains
obscure however, it is possible that RPMI-8226 cells produce
a factor or hormone that acts as a potent inducer of
endogenous 'C' type virus. A similar mechanism has been
proposed to account for the induction of MuLV in nude
mice bearing an oat cell carcinoma xenograft (Gautsch et al.,
1980).
Our results emphasize a serious pitfall that may be
encountered when handling human tumour material as xeno-
grafts. Without examination of the resultant tumour cells in
vitro for their growth pattern and against a panel of
monoclonal antibodies directed against murine as well as
human tissue any conclusion concerning the drug sensitivity
of our myeloma cell line in vivo would have been mean-
ingless. Furthermore, the data suggest that RPMI-8226 cells
should be handled with caution since their ability to initiate
the production of retrovirus may not be limited to viruses of
murine origin.
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